New Director in Charge at Clinilabs Europe

Clinilabs has recruited a former IQVIA and Eli Lilly executive to lead the company’s European growth.

The firm appointed Anne-Marie Nagy, Ph.D., as executive vice president and head of Clinilabs Europe. The company expanded its European operations earlier this year, establishing its EU headquarters at the Switzerland Innovation Park Basel Area, a part of the country’s national innovation network and located within the Basel region’s globally recognized life sciences cluster.

“Europe is a critical pillar of Clinilabs’ long-term growth strategy,” Clinilabs President/CEO Gary K. Zammit, Ph.D., said. “Establishing our EU headquarters positions us within one of the world’s most concentrated life sciences ecosystems. Combined with Dr. Nagy’s leadership, this expansion enhances our ability to serve European sponsors with senior-level engagement and localized leadership, increasing our ability to support European clinical programs and meet regional regulatory requirements.”

Dr. Nagy has more than 25 years of global experience in clinical drug development, operational strategy, and P&L leadership across pharmaceutical and contract research organizations. She will lead Clinilabs’ European growth strategy, oversee EU financial performance, and direct cross-functional teams to deliver operational excellence and sustainable profitability.

Dr. Nagy is a proven builder of high‑performing therapeutic business units and has delivered consistent double‑digit revenue growth and strong EBITDA results, with prior senior leadership roles at TFS HealthScience, Premier Research, IQVIA, PPD, Eli Lilly, and SMB Laboratories. Her therapeutic expertise spans neuroscience, psychiatry, rare and pediatric diseases, and advanced gene therapies across Europe, the United States, Asia‑Pacific, Latin America, and South Africa.

Dr. Nagy earned a PhD in biomedical sciences (Summa Cum Laude) from the Free University of Brussels, completed an executive business certification program at the Stockholm School of Economics, and has served as an expert for the European Network for Women in Technology.

“I am excited to lead Clinilabs’ European organization during this important phase of growth,” Dr. Nagy said. “The choice for our EU headquarters positions Clinilabs at the center of a collaborative and scientifically advanced environment. I look forward to expanding our European footprint and delivering exceptional value to our clients.”

Clinilabs is a global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug, device, and technology development. Drawing on deep, indication-level expertise, a proven process, the latest technology, and global reach spanning North America, the EU, and beyond, Clinilabs expertly manages Phase 1-3 trials to accelerate treatments for a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS disorders.